高血圧患者における服薬アドヒアランスと機能性食品の使用:横断研究
Hidehiro Someko1,2,3,4, Takeo Nakayama5, Shiho Koizumi6
1Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. hidehirosomeko@gmail.com.
まとめ
高血圧の治療に機能性食品を使用している患者は、服薬アドヒアランスが低いリスクが高いことが示された。これは、機能性食品の使用と処方薬の治療アドヒアランスが最適ではないこととの関連を示唆している。
科学分野:
- 心血管健康
- 栄養科学
- 公衆衛生
背景:
- 機能性食品は、高血圧などの慢性疾患を持つ患者にますます採用されている。
- 機能性食品の摂取と高血圧患者の服薬アドヒアランスとの関係は、よく理解されていない。
主な方法:
- ジャパンCOVID-19と社会インターネット調査(JACSIS 2024)のデータを利用した横断研究。
- 適格基準:降圧薬を服用中の自己申告高血圧の成人。
- 服薬アドヒアランスは、Japanese 8-item Morisky Medication Adherence Scale(MMAS-8)を用いて評価され、低アドヒアランスはMMAS-8 < 6と定義された。
結論:
- 高血圧患者における機能性食品の治療的使用は、処方された降圧療法へのアドヒアランスが最適ではないことと関連している可能性がある。
- この関連性と潜在的な根本的なメカニズムをさらに調査する必要がある。
- 横断的デザインでは因果関係の推論はできず、自己申告データは測定誤差を導入する可能性がある。
関連する概念動画
Hypertension IV: Drug Therapy and Lifestyle Modifications
618
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
618
Hypertension V: Nursing Management
355
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
355
Heart Failure VI: Adjunct Therapies
252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Hypertension III: Clinical Manifestations and Diagnostic Studies
465
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
465
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143

